激素替代疗法（Hormone replacement therapy, HRT）是指为身体补充随着年龄增长而减少的激素，主要是雌激素、孕酮和睾酮。HRT 最初是为治疗更年期症状而开发的，但基于其对与衰老相关的健康结果和生物标志物影响的新兴证据，它作为一种潜在的延寿干预措施已引起了广泛关注。
HRT 旨在将激素水平恢复到更年轻的范围，从而可能缓解多个生理系统与年龄相关的衰退。现代方法强调通过最佳途径和时机输送生物等效激素（bioidentical hormones），以在将风险降至最低的同时实现益处最大化。
生物等效形式：
给药方式：
- 透皮贴剂或凝胶（首选）
- 口服片剂
- 阴道制剂
- 舌下制剂¹
生物同质性孕酮（Bioidentical Progesterone）：
合成孕激素（Synthetic Progestins）（较不推荐）：
女性：
男性：
线粒体功能：
- 雌激素增强线粒体生物发生和能量产生
- 支持细胞呼吸和 ATP 合成
- 减少氧化应激⁵
心血管保护：
- 改善内皮功能和血管舒张
- 支持健康的胆固醇水平
- 减少炎症⁶
骨骼健康：
- 通过抑制破骨细胞活性来维持骨密度
- 刺激成骨细胞功能
- 保护骨微结构⁷
认知功能：
- 支持神经可塑性和神经递质的产生
- 预防神经退行性病变
- 维持记忆力和执行功能⁸
皮肤与结缔组织：
- 刺激胶原蛋白生成
- 维持皮肤弹性和厚度
- 支持伤口愈合⁹
心血管疾病：
- Women's Health Initiative 的20年随访显示，在绝经后10年内开始 HRT 不会增加心血管疾病的死亡率¹⁰
- 在适当时机开始治疗可将整体心血管死亡率降低 30-50%¹¹
- 对脂质谱和动脉功能有良好影响¹²
癌症预防：
- 对于无子宫的女性，仅使用雌激素的治疗与乳腺癌风险增加无关¹³
- 使用雌激素加微粒化黄体酮 (micronized progesterone) 的前5年内，乳腺癌风险没有增加¹⁴
- 可能降低结直肠癌风险¹⁵
骨骼健康：
- 显著降低骨折风险（髋部骨折减少 50-70%）¹⁶
- 维持骨矿物质密度
- 预防骨质疏松相关的并发症¹⁷
认知功能：
- 在绝经早期开始治疗可能有助于保持认知功能
- 在一些研究中降低了痴呆症的风险
- 支持记忆力和处理速度¹⁸
全因死亡率：
- 在合适的候选人群中，可将整体死亡率降低高达 40%¹⁹
- 在绝经后10年内开始治疗获益最大²⁰
- 长期随访研究证实了对死亡率的益处²¹
研究已记录了与衰老相关的生物标志物的改善：
- 炎症标志物 (CRP, IL-6)²²
- 胰岛素敏感性和葡萄糖代谢²³
- 脂质谱和心血管标志物²⁴
- 骨转换标志物²⁵
2024年发表的 Women's Health Initiative 的20年随访显示，乳腺癌或心血管疾病的死亡人数没有增加，这代表了对 HRT 长期安全性特征理解的重大转变²⁶。
透皮雌激素与口服雌激素：
- 由于血栓风险较低，首选透皮雌激素
- 透皮途径不会增加静脉血栓栓塞的风险
- 对肝脏代谢和凝血因子的影响较小²⁷
生物等效激素与合成激素：
- 生物等效黄体酮 (Bioidentical progesterone) 比合成孕激素表现出更好的安全性特征
- 与非生物等效制剂相比，血栓风险降低
- 具有更好的脂质谱和血管效应²⁸
初始适应期：
- 不规则阴道出血（通常在6个月内缓解）²⁹
- 乳房触痛或肿胀³⁰
- 轻度体液潴留³¹
- 适应期内的情绪变化³²
雌激素相关效应：
- 恶心（口服制剂更常见）
- 头痛（调整剂量后可能改善）
- 乳房触痛³³
孕激素相关效应：
睾酮相关效应（女性）：
- 轻度痤疮
- 性欲增加
- 毛发生长改变
- 声音改变（在适当剂量下罕见）³⁵
血栓事件：
- 口服雌激素会增加风险（透皮制剂不会）
- 使用第一年的风险最高
- 健康女性的绝对风险仍然很低³⁶
中风风险：
- 口服雌激素会轻微增加风险
- 透皮雌激素不会增加风险
- 对于合适的候选者，风险收益比倾向于接受治疗³⁷
乳腺癌：
- 联合治疗5年以上会小幅增加风险
- 单一雌激素治疗不会增加风险
- 风险因激素类型和持续时间而异³⁸
胆囊疾病：
- 患有乳腺癌或有乳腺癌病史（在某些情况下为相对禁忌）⁴⁰
- 患有子宫内膜癌或有子宫内膜癌病史⁴¹
- 活动性血栓栓塞性疾病⁴²
- 活动性肝病⁴³
- 不明原因的阴道出血⁴⁴
- 怀孕⁴⁵
- 静脉血栓栓塞病史
- 心血管疾病（取决于发生时间和类型）
- 伴有先兆的偏头痛
- 胆囊疾病
- 伴有并发症的糖尿病⁴⁶
时间窗口:
- 绝经后 10 年内为最佳起始时间
- 心血管益处的“关键窗口假说”
- 较早开始治疗与更好的预后相关⁴⁷
个体风险评估:
- 激素敏感性癌症家族史
- 个人心血管风险因素
- 基线血栓风险
- 遗传因素（如 Factor V Leiden）⁴⁸
雌激素剂量:
- 经皮雌二醇：每天 0.025-0.1 mg
- 口服雌二醇：每天 1-2 mg
- 根据症状和反应进行个体化调整⁴⁹
孕酮（适用于有子宫的女性）:
- 微粒化孕酮：每天 100-200 mg（口服）
- 连续或周期性给药
- 孕酮栓剂：100-200 mg⁵⁰
睾酮（女性可选）:
- 低剂量睾酮乳膏：每天 1-5 mg
- 仔细监测副作用
- 未获 FDA 批准用于女性⁵¹
生物等效激素优化:
- 激素水平监测与调整
- 达到年轻范围的生理剂量
- 定期监测安全指标⁵²
联合方法:
- 多重激素替代（雌激素、孕酮、睾酮）
- 生长激素考量
- DHEA 补充⁵³
初步评估：
- 全面的病史
- 体格检查，包括乳房和盆腔检查
- 基线实验室检查⁵⁴
持续监测：
- 年度乳房X光检查和乳房检查
- 定期盆腔检查
- 血压监测
- 肝功能检查⁵⁵
激素水平监测：
- 雌二醇水平
- 孕酮水平（如适用）
- 睾酮水平
- SHBG（性激素结合球蛋白）⁵⁶
- 血脂谱
- 炎症标志物
- 凝血功能检查（如有指征）
- 骨密度评估⁵⁷
- FDA批准的HRT：每月 $30-200
- 复合生物等效激素：每月 $100-500
- 监测和实验室费用：每年 $200-500
- 针对长寿应用的保险覆盖范围各不相同⁵⁸
- 通过医疗保健提供者可广泛获得
- 专业的长寿诊所提供优化方案
- 远程医疗选项日益普及
- 复合制剂需要专门的药房⁵⁹
- 关于抗衰老应用的长期数据有限
- 尚未确立用于长寿的最佳给药方案
- 个体反应差异尚未得到充分描述
- 联合治疗的数据有限⁶⁰
- 获 FDA 批准用于治疗更年期症状
- 抗衰老应用被视为超适应症（off-label）使用
- 配制制剂（Compounded preparations）的监管有限
- 非 FDA 批准产品存在质量和一致性问题⁶¹
- 基于遗传学的个性化激素优化
- 新型递送系统和配方
- 与其他长寿干预措施相结合
- 生物标志物指导的治疗方案⁶²
- 连续激素监测系统
- 精准给药算法
- 新型激素配方
- 远程医疗整合⁶³
激素替代疗法（HRT）是一种成熟的干预措施，越来越多的证据表明，在适当使用的情况下，它具有延长寿命的益处。安全有效的 HRT 的关键在于正确的患者选择、最佳的时机、生物等效激素的选择、合适的给药途径以及仔细的监测。虽然存在风险，但近期的长期随访数据表明，在遵循现代方案的情况下，这些风险是极小的。
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.
- Simon JA, Robinson DE, Andrews MC, et al. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril. 1993;60(1):26-33.
- Davis SR, Worsley R, Miller KK, et al. Androgens and female sexual function and dysfunction--findings from the Fourth International Consultation of Sexual Medicine. J Sex Med. 2016;13(2):168-178.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
- Yao J, Irwin RW, Zhao L, et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106(34):14670-14675.
- Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801-1811.
- Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279-302.
- Sherwin BB. Estrogen and cognitive functioning in women: lessons we have learned. Behav Neurosci. 2012;126(1):123-127.
- Verdier-Sévrain S, Bonté F. Skin hydration: a review on its molecular mechanisms. J Cosmet Dermatol. 2007;6(2):75-82.
- Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials. JAMA. 2020;324(4):369-380.
- Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231.
- Rosano GM, Vitale C, Marazzi G, et al. Menopause and cardiovascular disease: the evidence. Climacteric. 2007;10 Suppl 1:19-24.
- Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
- Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289(24):3243-3253.
- Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991-1004.
- Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290(13):1729-1738.
- Wells GA, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23(4):529-539.
- Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. Climacteric. 2012;15(3):256-262.
- Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
- Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231.
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938.
- Vural P, Akgül C, Yildirim A, et al. Antioxidant defence in premenopausal women and changes with hormone replacement therapy and nonhormonal therapies. Maturitas. 2006;55(3):267-273.
- Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004;47(7):1175-1187.
- Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325(17):1196-1204.
- Garnero P, Sornay-Rendu E, Chapuy MC, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11(3):337-349.
- Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials. JAMA. 2020;324(4):369-380.
- Olie V, Plu-Bureau G, Conard J, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18(5):488-493.
- L'hermite M, Simoncini T, Fuller S, et al. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas. 2008;60(3-4):185-201.
- Mattsson LA, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas. 1982;4(2):95-102.
- Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92(6):982-988.
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
- Ibid.
- The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.
- Montplaisir J, Lorrain J, Denesle R, et al. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause. 2001;8(1):10-16.
- Davis SR, Worsley R, Miller KK, et al. Androgens and female sexual function and dysfunction--findings from the Fourth International Consultation of Sexual Medicine. J Sex Med. 2016;13(2):168-178.
- Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-845.
- Renoux C, Dell'aniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519.
- Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-1168.
- Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005;293(3):330-339.
- Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427.
- Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85(2):304-313.
- Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277-2286.
- Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103(5):638-642.
- The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.
- Ibid.
- Ibid.
- Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231.
- The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.
- Simon JA, Robinson DE, Andrews MC, et al. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril. 1993;60(1):26-33.
- Davis SR, Worsley R, Miller KK, et al. Androgens and female sexual function and dysfunction--findings from the Fourth International Consultation of Sexual Medicine. J Sex Med. 2016;13(2):168-178.
- Harman SM, Naftolin F, Brinton EA, et al. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci. 2005;1052:43-56.
- Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994;78(6):1360-1367.
- The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.
- Ibid.
- Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87(6):706-727.
- The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.
- National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE guideline [NG23]. 2015.
- Ibid.
- Harman SM, Naftolin F, Brinton EA, et al. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci. 2005;1052:43-56.
- Iftikhar S, Collazo-Clavell ML, Roger VL, et al. Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med. 2012;70(2):74-80.
- Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry. 2015;72(7):714-726.
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.